Adolf Johann Friedrich von Baeyer was born in Berlin in 1835 and developed a fascination with chemistry at a very early age. By the age of 12 he had synthesized a new salt from copper and begun a lifelong research project into the oxidation process of indigo. After gaining a Ph.D. on arsenic compounds, he moved to Ghent and began research into uric acid. This work led him to the synthesis of malonylurea, a reaction of urea with malonic acid. This compound came to be known as barbituric acid. Interestingly, although his thesis on uric acid secured his employment as a teacher in Berlin, it was not the focus of his life's work. He was eventually awarded the Nobel Prize for chemistry in 1905 for the development of organic chemistry and his work on organic dyes and hydroaromatic combinations.
It is unclear why Baeyer was attempting to create barbituric acid. The compound is hypnotically inert and he does not appear to have been motivated by the therapeutic implications. However, he was apparently quite excited by the discovery, and legend has it that he celebrated that night at a nearby tavern. Also in the tavern were a number of artillery officers celebrating the day of their patron saint, St Barbara. Supposedly Barbara was amalgamated with urea to give the name barbiturate. Unfortunately there is no way of authenticating this story but it is firmly entrenched in the history books.
Fischer and Von Mering synthesized diethyl barbituric acid in 1903. This was the first sedative barbiturate and was named Veronal, supposedly after Mt Verona in Italy where Fischer had recently been travelling. This oral barbiturate was popular for many years but was very long-acting.
The first barbiturate to be used intravenously was Somnifen (also marketed as Somnifaine), a combination of two barbiturates, barbital (Veronal) and diallylbarbituric acid (Dial). This agent was created in 1920 by T. A. Redonnet and first used in labour ward by Cerne. In 1924 it was used by Fredet and Perlis for surgical procedures and was then used for many years in France and Germany. It was not used widely outside of Europe although J. H. Fjelde reported its use in Dakota in 1929 for surgery and obstetrics. His technique involved giving the intravenous component in the ward prior to an ethylene anaesthetic. "We are now using a 3 cc dose in most cases. This does several things. In the first place the patient is put to sleep right in his room, a distinct advantage which relieves him of further thoughts of the coming operation. Patients appreciate this feature ... When awakening they are back in their own bed and have no recollection of having been to the operating room at all. A wonderful feature!" His use in obstetrics sounds even more delightful. "In the average sized woman, the injection of 6 cc will last six hours, as a rule ... On awakening they do not even remember me having taken out the needle." He stated that labour was not unduly affected, that the child may be somnolent but otherwise unaffected, and that there was no problem with haemorrhage or altered reflexes. When commenting on the drowsiness afterwards he states that "I do not regard this as a drawback, as the rest does the patient good." He also adds, "Should it be desirable to awaken the patient shortly after delivery, an ampoule of caffeine-sodium benzoate will usually accomplish this in one half to one hour. The patient will then recognize relatives and talk rationally, but later may not remember this phase."
In 1927, the German obstetrician, Bumm, introduced Pernocton, a sodium sec-butyl-(2-bromoallyl)-barbiturate. This drug became much more popular although it had few, if any, advantages over Somnifen. Later it was marketed as a 10% aqueous solution and the name was changed to Pernoston. Neither Pernoston nor Somnifen fulfilled the modern criteria for good induction agents as they had relatively slow onset and very slow recovery times.
Helmut Weese (1897-1954) graduated from medicine at Munich University but soon changed direction to become a pharmacologist. By 1928 he was head of the department of pharmacology at the Bayer works in Wuppertal-Elberfeld. He later became Professor of Pharmacology in Cologne and then Dusseldorf. It should be noted that these Bayer works were the original site of what is now a worldwide chemical industry. However, although they did significant work into the development of intravenous barbiturates, the company has no relation to Adolf von Baeyer, despite the connection being made by various educational websites. The Bayer Company was founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott and was originally a dye works.
The first truly short acting barbiturate, hexobarbitone (Evipan, Evipal), was synthesized under the direction of Helmut Weese and its first clinical use was reported by Weese and W. Scharpff in July 1932. The drug soon became extremely popular as an induction agent and by 1944 Adams estimated that it had been used on over two million patients over 10 years. Its main side-effect was excitatory muscle movement which was a feature common to all the methylated barbiturates.
Several other intravenous barbiturates appeared around this time but none were as effective as hexobarbitone. Hexobarbitone remained extremely popular long after the introduction of thiopentone.
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